We are pleased to announce that Tarsier Pharma will participate in the American Uveitis Society Fall meeting, which will be held in conjunction with the AAO Annual Meeting in San Francisco on Sunday, November 5, 2023.
At the conference, Dr. Edmund Tsui, a uveitis expert and principal investigator in the TRS4Vision Phase 3 clinical trial, will present insights from the clinical trial results at 08:38 PM.
Additionally, Dr. Daphne Haim-Langford, Tarsier’s CEO, will be delighted to meet for 1×1 meetings with uveitis experts and investors.
For more information, click here.
To register, click here.
Investor Relations – Tarsier Pharma